Johnson & Johnson (NYSE:JNJ) Receives $236.91 Consensus Price Target from Analysts

Shares of Johnson & Johnson (NYSE:JNJ) have received a consensus recommendation of “Moderate Buy” from the twenty-seven brokerages that are covering the stock, Marketbeat Ratings reports. Nine investment analysts have rated the stock with a hold recommendation, seventeen have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $237.5652.

A number of brokerages recently issued reports on JNJ. JPMorgan Chase & Co. raised their price target on Johnson & Johnson from $225.00 to $250.00 and gave the stock a “neutral” rating in a research note on Thursday, March 5th. Scotiabank reissued an “outperform” rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Guggenheim raised their price target on Johnson & Johnson from $240.00 to $244.00 and gave the stock a “buy” rating in a research note on Tuesday. Leerink Partners raised their price target on Johnson & Johnson from $201.00 to $232.00 and gave the stock a “market perform” rating in a research note on Thursday, January 22nd. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $255.00 price target on shares of Johnson & Johnson in a research note on Monday, March 30th.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,598,700.17. This trade represents a 21.22% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Timothy Schmid sold 1,322 shares of the firm’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the transaction, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 30,142 shares of company stock valued at $7,360,528 over the last three months. 0.16% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. J. Derek Lewis & Associates Inc. purchased a new position in Johnson & Johnson during the 4th quarter worth $296,000. Purpose Unlimited Inc. purchased a new position in Johnson & Johnson during the 4th quarter worth $131,000. Cornerstone Planning LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $4,442,000. Rockefeller Capital Management L.P. increased its holdings in Johnson & Johnson by 12.7% during the 4th quarter. Rockefeller Capital Management L.P. now owns 937,751 shares of the company’s stock worth $194,068,000 after purchasing an additional 105,383 shares during the period. Finally, Bank of New Hampshire increased its holdings in Johnson & Johnson by 4.8% during the 4th quarter. Bank of New Hampshire now owns 14,480 shares of the company’s stock worth $2,997,000 after purchasing an additional 660 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $241.13 on Tuesday. The firm has a market capitalization of $580.78 billion, a price-to-earnings ratio of 21.82, a PEG ratio of 2.39 and a beta of 0.34. Johnson & Johnson has a 1 year low of $145.13 and a 1 year high of $251.71. The business has a 50 day simple moving average of $241.07 and a 200-day simple moving average of $214.54. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The business had revenue of $24.28 billion during the quarter. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: TD Cowen reiterated a Buy and set a $250 price target, underpinning near-term upside expectations from improving fundamentals and pipeline momentum. TD Cowen Buy, $250 PT
• Positive Sentiment: Citi and other brokers have raised price targets and highlighted J&J’s stronger MedTech outlook, supporting bullish analyst sentiment that could prop the shares if Q1 confirms recovery. Citigroup Forecasts Strong Price Appreciation for JNJ
• Positive Sentiment: J&J launched the VARIPULSE Pro pulsed field ablation system in Europe (CE mark), adding a potential growth driver for its MedTech segment as real‑world studies and conference data are collected. This rollout is a concrete revenue catalyst if adoption scales. Johnson & Johnson PFA Launch Puts VARIPULSE Pro And Valuation In Focus
• Neutral Sentiment: Coverage pieces in Barron’s and TipRanks emphasize the rebound narrative heading into earnings, raising visibility but not adding new fundamental proof — they may support sentiment but won’t move the stock without data. Buy Johnson & Johnson Ahead of Earnings
• Neutral Sentiment: Market / media mentions (lists, S&P visibility) and multiple analyst notes increase attention; these can amplify moves but are secondary to earnings and device adoption. JNJ Gains Visibility As S&P 500 Trends Shift
• Negative Sentiment: Zacks warns that rising biosimilar competition and pricing pressure remain material headwinds for J&J’s pharma business; those risks mean the upcoming Q1 print could produce downside if guidance or growth details disappoint. Should You Buy, Sell or Hold JNJ Ahead of Q1
• Negative Sentiment: Upcoming Q1 estimates and metric expectations introduce short‑term volatility: if reported drug growth or MedTech momentum falls short of elevated analyst hopes, the stock could underperform. Wall Street Estimates for JNJ Q1

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.